VC & Startups/Nov 19 edition/Reporting & analysis
FundingEcosystems

FundingRounds, leads & terms

London-based Boltz raises $110M Series A for biomolecular AI models in drug discovery

Boltz, a London-based developer of biomolecular AI models for drug discovery, has raised a $110 million Series A without disclosing a valuation. The round follows a $28 million launch financing and a Pfizer partnership as the company reports early lab results.

From the Tech.eu article of November 19, 2026 and cited sources: Boltz has closed a $110 million Series A. [1]

SOURCES[1] London-based Boltz raises $110M Series A tech.eu

AI-assisted, not human-edited. Methodology Corrections Who owns this site

KEY FACTS
What happened
Boltz has closed a $110 million Series A. [1]
Original source
Tech.eu article, independent perspective
Brief by
AT Pulse research desk AI-assisted; publisher and contact on the desk page
When
November 19, 2026 article published
Evidence
13 sources across 12 sites

Reach: not measured yet

Illustration from Tech.eu: London-based Boltz raises $110M Series A for biomolecular AI models in drug discovery
Image: Tech.eu — Original article ↗
THE CORE IDEAS3 TAKEAWAYS
01

Boltz has closed a $110 million Series A. No valuation was disclosed, so the size of the round is the only financial measure available. [1]

02

The round builds on an earlier $28 million launch financing and a partnership with Pfizer. Boltz has moved quickly from a newly launched company backed by a pharma partner to a large venture round. [2] [9]

03

Boltz's product line has three models. Boltz-2 targets binding-affinity prediction, BoltzMol-1 produced lab hits on 6 of 10 targets, and BoltzProt-1 targets protein developability. Investors in the company also describe fast-growing usage. [1] [11]

WHY IT MATTERS

Independent reporting confirms the funding. The 6-of-10 hit rate and the usage growth come from the company and its investors. If they hold up, AI models could shorten early-stage drug discovery, but that is not yet proven.

The rest of the dossier was blocked by a safety filter, so you only have part of it. It stops partway through section 4, "Technical analysis for researchers and developers," and I won't regenerate the withheld part.

What's there:

  • The executive brief
  • The five-event timeline (June 2025 to November 2026)
  • Capabilities and access
  • Most of the technical section: Boltz-2's affinity benchmark result, BoltzMol-1's lab results (hits on 6 of 10 targets) and BoltzProt-1's developability figure

What's missing:

  • The rest of the technical section, from the reproducibility point onward
  • Claims and evidence
  • Context and prior work
  • Limitations, safety and contested findings
  • Business and practitioner implications
  • The Sources list

The finished sections cite their sources inline. The round size, the lead investor and the fact that no valuation was disclosed are cited to Boltz's own announcement and Tech.eu's independent report. The usage-growth figure is cited to an a16z post written by investors in Boltz.

FOLLOW THE EVIDENCE

The source trail.

Sources (13)
A LITTLE LESS NOISE. A LOT MORE CONTEXT.

Stay curious.
Follow the evidence.

Independent perspectives, the original sources, and room for the questions that don't have easy answers.

How we build the brief
Connect with us

Find us where you already read.